Open AccessSelexipag for the Treatment of Pulmonary Arterial Hypertension
Author(s) -
Olivier Sitbon,
Richard N. Channick,
Kelly Chin,
Aline Frey,
Seán Gaine,
Nazzareno Galiè,
Hossein A. Ghofrani,
Marius M. Hoeper,
Iréne Lang,
Ralph Preiss,
Lewis J. Rubin,
Lilla Di Scala,
Victor F. Tapson,
И. Э. Адзерихо,
Jinming Liu,
О. М. Моисеева,
Xiaofeng Zeng,
Gérald Simonneau,
Vallerie V. McLaughlin
Publication year - 2015
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1503184
Subject(s) - medicine , pulmonary hypertension , cardiology , intensive care medicine
In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom